FDA Approves Durvalumab Plus Chemo for Biliary Tract Cancer
The immune checkpoint inhibitor is already approved for use in lung cancer. Now it is also approved for use in combination with chemotherapy for locally advanced or metastatic biliary tract cancer.
FDA Approvals
source https://www.medscape.com/viewarticle/980227?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/980227?src=rss
Comments
Post a Comment